Senhwa Biosciences, Inc. and Chaperone Therapeutics, Inc. have entered into an exclusive, worldwide license agreement for advanced small molecules that have therapeutic potential for diseases caused by protein misfolding.
Under the terms of the agreement, Chaperone will develop the licensed compounds and Senhwa is eligible to receive equity in Chaperone as well as development milestone payments, potentially totaling USD $102.7 million, as well as royalties on annual product sales.
“Chaperone’s protein folding technology platform is well placed to advance the development of Senhwa’s compounds,” commented Dr. Tai-Sen Soong, president and CEO of Senhwa Biosciences.
“Protein misfolding is the cause of many neurodegenerative diseases, and data from disease models demonstrate efficacy through enhancing the cellular protein folding capacity,” said Dennis J. Thiele, Ph.D., CSO of Chaperone Therapeutics.
“We are delighted to access the outstanding small molecule portfolio developed by Senhwa, to an advanced preclinical state, to address protein misfolding diseases”.
Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated.
Chaperone Therapeutics is developing frontline therapies to address protein misfolding and neuronal cell loss: the underlying causes of neurodegenerative disease.